Double Medical(SZ:002901) Sou Hu Cai Jing·2025-12-01 15:24Core Viewpoint - Dabo Medical (002901) shows a positive performance with a closing price of 49.46 yuan, up 2.68% as of December 1, 2025, indicating strong market interest and potential growth in the medical device sector [1]. Financial Performance - For the first three quarters of 2025, Dabo Medical reported a main revenue of 1.876 billion yuan, a year-on-year increase of 22.69% [2]. - The net profit attributable to shareholders reached 425 million yuan, reflecting a significant year-on-year growth of 77.03% [2]. - The third quarter alone saw a main revenue of 666 million yuan, up 17.82% year-on-year, with a net profit of 180 million yuan, also up 77.49% year-on-year [2]. - The company maintains a gross margin of 71.23%, which is significantly higher than the industry average of 51.22% [2]. Market Position - Dabo Medical's total market capitalization stands at 20.477 billion yuan, ranking 12th in the medical device industry [2]. - The company has a price-to-earnings ratio (P/E) of 36.17, which is lower than the industry average of 59.83, indicating a potentially undervalued stock [2]. - The return on equity (ROE) is reported at 12.83%, placing the company 7th in the industry rankings [2]. Capital Flow - On December 1, 2025, the net inflow of main funds was 6.1541 million yuan, accounting for 4.28% of the total transaction amount, indicating strong institutional interest [1]. - Over the past five days, there has been a mixed trend in capital flow, with retail investors showing a net outflow of 10.9273 million yuan on December 1, 2025 [1].